Slides on Key Decisions in HIV Care: What to Do About Missed CAB Plus RPV LA Injections?

Learn how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.
person default
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Format: Microsoft PowerPoint (.ppt)
File Size: 439 KB
Released: October 4, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Expert commentary on what long-acting ART means for people with HIV, from Dr Jean-Michel Molina and Clinical Care Options (CCO)

Jean-Michel Molina, MD, PhD Released: November 30, 2021

Commentary from Dr Karine Lacombe on the potential role of an investigational 2-drug regimen of lenacapavir plus islatravir, from Clinical Care Options (CCO)

Karine Lacombe, MD, PhD Released: November 30, 2021

Clinical Care Options (CCO) expert analysis of new data from EACS 2021, provided by expert HIV faculty

person default Tristan J. Barber, MA, MD, FRCP Released: November 30, 2021

One patient’s journey from HIV diagnosis to undetectable while trying to lose weight, from Clinical Care Options (CCO)

person default Anonymous Patient Released: November 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue